Navigation Links
Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology

he Saint Louis University School of Medicine, said, "The potential identification of an etiology for chronic sinusitis, and the subsequent development of an effective pharmacotherapy, would represent an important advance in the treatment of patients suffering from surgery refractory chronic sinusitis. This is one of the most common chronic illnesses, affecting millions, and the potential of intranasal antifungals to significantly reduce morbidity is tremendous."

Accentia has received Fast Track status from the Food and Drug Administration for SinuNase, and has initiated a Phase 3 clinical trial at sites across the U.S., in patients with severe chronic sinusitis who have had one or more prior sinus surgeries. Patients who believe they may be eligible to participate in a clinical trial with SinuNase are encouraged to visit www.accentia.net/patients/trials_sinunase.php, or call 212-686-4100.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of late-stage "disruptive" clinical products, especially for already-approved drugs in new formulations and/or new indications that are patent-protected and which represent new therapeutics with greater clinical and economic value. Accentia has a pipeline of products in late-stage clinical development. The company's lead respiratory product candidate is SinuNase(TM), which is under clinical development to treat chronic sinusitis (rhinosinusitis). SinuNase is a novel application and formulation of a known anti-fungal exclusively licensed from the Mayo Foundation for Medical Education and Research. The product has been Fast Tracked by the FDA and the Company has commenced a Phase 3 clinical trial. The Company's other lead product is BiovaxID(TM), a patient-specific anti-cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma. BiovaxID, which is being developed by Accentia's subsidiary, Biovest International, Inc., (OTCB
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
7. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
11. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
Post Your Comments:
(Date:10/30/2014)... , Oct. 30, 2014  Misonix, Inc. (NASDAQ: ... that designs, manufactures and markets innovative therapeutic ultrasonic instruments ... today that it will report financial results for the ... 2014. The Company has scheduled a conference call that ... ET to review the results. Interested ...
(Date:10/30/2014)... Mass. , Oct. 30, 2014   NxStage® Kidney ... NXTM ), is proud to host the grand ... center at 1600 W. 16 th Street on ... is operated by highly trained medical staff who are committed ... and quality of life benefits made possible through more flexible ...
(Date:10/30/2014)... 2014  Zimmer Holdings, Inc. (NYSE: ZMH ... leadership team and organizational structure of the combined company ... announced that the combined organization will leverage the strength ... Biomet, with the new brand to be rolled out ... merger.  The future leadership team is committed to establishing ...
Breaking Medicine Technology:Misonix, Inc. To Report First Quarter Fiscal Year 2015 Financial Results On Thursday, November 6, 2014 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9
... Cantel Medical Corp. (NYSE: CMN ) will ... ended July 31, 2011 on Thursday, October 13 before the ... results at 11:00 AM ET.  Participating in the call will ... CEO; Seth R. Segel, Executive Vice President; and Craig A. ...
... Microflex Corporation (Lake Forest, IL), a ... of latex and synthetic barrier protection products, is excited ... the first glove to receive an ergonomic certification.   ... Ergonomics, the leader in ergonomic testing and certifications in ...
Cached Medicine Technology:Cantel Medical Corp. to Hold Conference Call to Discuss Fourth Quarter and Fiscal 2011 Results 2Microflex XCEED®--First Certified Ergonomic Disposable Examination Glove 2
(Date:10/30/2014)... comes to heart disease, a new study finds women are ... symptoms that spell trouble. "The main danger is that ... or advanced stage of heart disease, there are simply fewer ... and research fellow at the Harvard School of Public Health, ... Foundation of Canada. In the study, researchers talked to ...
(Date:10/30/2014)... Amy Norton HealthDay Reporter ... a common plastics, chemical during pregnancy may have effects on ... Researchers found that baby boys born to moms with greater ... shorter anogenital distance -- the space between the genitals and ... considered a marker of exposure to androgens ("male" hormones) during ...
(Date:10/30/2014)... Many U.S. colleges have indoor tanning salons on ... risk for skin cancer, researchers report. Tanning ... so colleges should adopt tanning-free policies, to help ... health efforts are needed to raise university administration ... indoor tanning poses to young adults in order ...
(Date:10/30/2014)... opinions about the Affordable Care Act are sharply divided ... voters are strongly in favor of the Affordable Care ... Democrats want the next Congress to move ahead with ... current law, while 44 percent want to expand the ... want the law repealed, and 27 percent want it ...
(Date:10/30/2014)... respects the fact that a patient,s body is ... Over a third of cancer patients experience psychosocial ... conditions. And, increasingly, care providers are exploring phone- ... mental health challenges. A University of Colorado Cancer ... Psycho-Oncology asks an important question: after decades ...
Breaking Medicine News(10 mins):Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2
... day to analysis and expert thought, they may be able ... of the precise type of brain tumour they face. Now ... technique that can give a preliminary analysis of the precise ... the brain and nervous system and they account for 20% ...
... Rosemont, Ill. - June 17, 2008- Current protein recommendations ... newer research indicates that many adults may benefit from ... presented in a supplement in the May issue of ... describing the conclusions of a Protein Summit ...
... on invasion and migration in colorectal cancer cell line. This ... performed by a team led by Professor Ji-Kun Li from ... article to be published on April 21, 2008 in the ... of the main causes of cancer-related death in the world. ...
... 17 XTENT, Inc.,(Nasdaq: XTNT ) today announced ... the current issue of EuroIntervention was recognized by the,journal,s ... submitted to the,journal this past winter. Lutz Buellesfeld, M.D., ... of the study,s investigators, received,an award in conjunction with ...
... Ala., June 17 Emageon Inc.,(Nasdaq: EMAG ... for hospitals, healthcare networks and imaging facilities announced,today ... present at the,Jefferies 2nd Annual Healthcare Conference on ... 24th at 8:30 AM ET. The presentation will ...
... 17 Nutrition 21, Inc.,(Nasdaq: NXXI ), ... consumers manage blood sugar levels, improve cardiovascular health,enhance ... Skin,Rejuvenation(TM) a new Iceland Health-branded product. Skin Rejuvenation ... capsule form,designed to reduce, at the cellular level, ...
Cached Medicine News:Health News:Wavelets crunch through doctors' day long struggle to diagnose brain tumors 2Health News:Is it time to revisit the current protein recommendations? 2Health News:Is it time to revisit the current protein recommendations? 3Health News:XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention 2Health News:XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention 3Health News:Nutrition 21 Introduces New Product: Iceland Health Skin Rejuvenation(TM) 2Health News:Nutrition 21 Introduces New Product: Iceland Health Skin Rejuvenation(TM) 3
... The E-Holder™ Platform is designed with a ... 96 and E-Gel® 48 gel cassettes stay ... allows reproducible placement and loading from one ... make adjustments to the robot loading software. ...
... seamless eliminating the possibility of leakage around glued ... temperature resistant gel trays meaning you do no ... added user friendliness, the Primo tanks come with ... The Primo Gel Systems are designed to be ...
Designed for rapid, routine electrophoresis for nucleic acids. The Mini unit is designed with a choice of two casting systems: standard casting trays that require sealing tape; or aluminum-gated cast...
... gel system is designed for very fast and clear ... System allows the user to cast, run, and perform ... with : 1 x electrophoresis tank and cover, 1 ... 83 mm tray), 2 x MT-T02 (50 x 60 ...
Medicine Products: